Skip to main content

Protein Forest Closes $19M Series A

NEW YORK, Nov. 21 (GenomeWeb News) - Proteomics separations start-up ProteinForest announced today that it has closed a $19 million Series A financing.


The Watertown, Mass.-based company's technology consists of a suite of products centered around the ProteomeChip - developed by three Israeli physicists - which the company claims can separate and image all proteins in a biological sample in one hour or less, with high sensitivity, reproducibility, and accuracy. The company is currently led by CEO Russell Garlick, former vice president of R&D at PerkinElmer.


S.R. One, Boston Millennia Partners, IDG Venture, and Novo A/S led the Series A financing.


The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.